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Background: The 3′ splice site (SS) at the end of pre-mRNA introns has a consensus sequence (Y)nNYAG for
constitutive splicing of mammalian genes. Deviation from this consensus could change or interrupt the usage of
the splice site leading to alternative or aberrant splicing, which could affect normal cell function or even the
development of diseases. We have shown that the position “N” can be replaced by a CA-rich RNA element called
CaRRE1 to regulate the alternative splicing of a group of genes.
Results: Taking it a step further, we searched the human genome for purine-rich elements between the −3
and −10 positions of the 3′ splice sites of annotated introns. This identified several thousand such 3′SS; more than
a thousand of them contain at least one copy of G tract. These sites deviate significantly from the consensus of
constitutive splice sites and are highly associated with alterative splicing events, particularly alternative 3′ splice and
intron retention. We show by mutagenesis analysis and RNA interference that the G tracts are splicing silencers and
a group of the associated exons are controlled by the G tract binding proteins hnRNP H/F. Species comparison of a
group of the 3′SS among vertebrates suggests that most (~87%) of the G tracts emerged in ancestors of mammals
during evolution. Moreover, the host genes are most significantly associated with cancer.
Conclusion: We call these elements together with CaRRE1 regulatory RNA elements between the Py and 3′AG (REPA).
The emergence of REPA in this highly constrained region indicates that this location has been remarkably
permissive for the emergence of de novo regulatory RNA elements, even purine-rich motifs, in a large group of
mammalian genes during evolution. This evolutionary change controls alternative splicing, likely to diversify
proteomes for particular cellular functions.
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Alternative splicing is the major source of proteomic
diversity in vertebrates [1-3]. It occurs in more than 90%
of human genes and plays important roles in cell func-
tion and the development of diseases [4-8]. The usage of
alternative exons is tightly regulated in cells in a spatial
and temporal manner by cis-acting RNA elements and
trans-acting factors [9,10]. Cis-acting elements have
been identified around or overlapping with motifs of the
splice sites. It is however very rare for a de novo regulatory* Correspondence: xiej@umanitoba.ca
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unless otherwise stated.element to exist between the polypyrimidine tract and 3′
AG of the 3′ splice site (3′SS), apparently due to the
constrained sequence and space of the motifs for proper
splicing [11-13].
The 3′ splice sites at the end of introns have a highly
conserved arrangement of consensus sequence (Y)nNYAG
[13], where the polypyrimidine tract (Py) is close to the 3′
AG for the binding of the heterodimmeric U2AF65 and
U2AF35 [13], respectively. The space between the (Y)n
and 3′ AG is highly constrained: simply increasing the
distance weakens splice site usage [14].
We have shown previously that a CA-rich element
called CaRRE1 is within this 3′SS space and bound by
hnRNP L to regulate depolarization-induced splicing
[15-20], but it is not clear whether a purine-rich elementThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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well-characterized purine-rich splicing regulatory elements
are guanidine (G) tracts containing a minimal functional
G3 [21], mostly as silencers in exons or enhancers in in-
trons [21-23]. Here we searched the human genome for
such potential elements and report the identification and
characterization of a large group of G tracts between the
(Y)n and 3′ AG, which we call with other elements at this
special location REPA (regulatory RNA elements between
the Py and 3′AG).Results
REPA G tracts within a group of human 3′SS
To determine if there are purine-rich REPA like the
CaRRE1, we searched the 3′SS of annotated introns in the
human genome for those with >60% A/G content within
the −10 ~ −3 nucleotides of the intron end (Figure 1A-B),
a length sufficient to harbor a splicing regulatory RNA
element. This identified 5,041 unique 3′SS of 3′AG
introns. On average, the A/G content between the −10
and −5 positions is about 70% compared to only aboutFigure 1 Identification of a large group of 3′SS that contain Purine-ric
3′AG. A. Diagram showing the location of purine-rich sequences (Pu) betw
the human genome. The U2AF65/35 heterodimer, which normally bind the P
sequences between them. B. Percent of A/G at the 3′SS of human cons
elements (black solid line, n = 5041 3′SS) as in A. The p values, obtained by hy
and −3. C. Percent of A/G shown in the context of individual nucleotides at e
(Right) 3′SS.20% for that of constitutive exons (Figure 1B-C). At
the −4 and −3 positions, the A/G content is also higher,
about 40% over the constitutive ones. Overall, the A/G
content between the −10 and −3 positions is significantly
higher (p = 0 for each position in hypergeometric test)
than that of constitutive exons.
To identify consensus elements, we examined the nu-
cleotides −15 to -3 nt to allow for a maximal 5 upstream
nucleotides to form elements with the search target
sequence. These sequences were subject to the MEME
(multiple Em for motif elicitation) analysis as reported
previously [24,25]. This identified G-rich motifs, among
others (Figure 2), as one of the top consensus elements.The REPA G-tracts are highly associated with alternative
splicing
To determine the strength of the splice sites containing
the purine-rich elements, we calculated their MaxEntS-
can entropy scores, as described by Yeo and Burge [26].
The scores are significantly lower than the 3847 3′SS
randomly chosen from the human genome, with thoseh sequences between the −3 and −10 positions in front of the
een the polypyrimidine tract (Py) and 3′ AG of constitutive exons in
y and 3′ AG, respectively, could be disrupted by the presence of Purine
titutive 3′SS (dotted pink line, n = 4620 3′SS) or 3′SS with Pu-rich
pergeometric test, are 0 for all the nucleotide positions between −10
ach position of the 4620 constitutive (Left) or Pu-rich element-harboring
DFigure 2 The sequences of the purine-rich-element-harboring 3′SSs deviate from the constitutive 3′SS (A) and a group of them are
significantly associated with alternative splicing (B-D). A. Entropy scores of the 3′SS. n = 3847, 76, 411, 71, 35, 46, 125, 131, 99 of 3′SS for
columns from left to right, respectively. *: of constitutive exons from the human genome, which are overall Py-rich (Figure 1B). The range of the
Student’s t-test p values of the constitutive versus each of the other groups of splice sites containing purine-rich elements are indicated. B. Abundance
of alternative splicing associated with different 3′SS sequence between the Py and 3′AG. For this graph, the percentages of alternative exons relative to
the total number of exons in each group were first obtained by analysis in the UCSC Genome Browser, ranging from 33% for the aaataa to 82% for
the ggaaa groups, respectively. The percentage for the group of randomly chosen exons was taken as the baseline abundance 1 (dotted line); the
percentages for the other groups were all normalized to it. *: a group of exons randomly chosen from the human genome. nt(−3): nucleotide at
the −3 position of 3′splice sites, which is a “y” for constitutive sites. n: any nucleotide, r: purines A or G. n = 24, 63, 169, 162, 36, 121, 38 of 3′SS for
columns from left to right, respectively. The p value was obtained by hypergeometric test for the abundance of alternative splicing of the G pentamer
group in the whole population of 3′ splice sites examined. C. Histogram showing the distribution of the first Gs of G tracts of 627 alternative exons
within the 3′SS. The first Gs peak at −10 and −8. D. Pie-shaped distribution of G tracts of the 737 alternative exons ranging from 3 to 8 Gs in a run, with
G3–5 comprising ~98%.
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lowest (Figure 2A, p = 3.8E-06 ~ 3.8E-39). Therefore, the
purine-rich REPA likely weakens the 3′SS.
To determine whether these 3′SS are associated with
alternative splicing, we examined some of the REPA-
containing 3′SS and their downstream exons of human
mRNA or expressed sequence tags (EST) in the UCSC
Genome Browser. The abundance of associated alter-
native splicing showed a general trend consistent with
entropy scores, for example, higher abundance among
exons with 3′SS containing the G pentamer (Figure 2B,
p = 9E-07). However, further comparison among three
groups of 3′SS (Figure 1A, gtggaa, ggggg and gaaaa
groups) with similarly low entropy scores (around 0,
p > 0.05 by t-test) indicated that not all of them were
associated with higher abundance of alternative spli-
cing. For instance, the gaaaa group had only about
half of the G pentamer group in the abundance. Thus,
specific purine sequences are likely also associated with
the high abundance of alternative splicing.
We then chose to focus on the REPA G tracts. We
examined in total 922 REPA G3–8-harboring 3′SS andfound 627 of them (68%) associated with alternative spli-
cing events (Additional file 1: Table S1). The first G mainly
starts between the −11 and −6 positions (Figure 2C), and
about 99% of them are G3–5(Figure 2D).
Major types of the associated alternative splicing
events include alternative 3′SS or 5′SS usage, cassette
exon and intron retention (Figure 3A). Of these, intron
retention has the most enrichment, about 17 times of
that surveyed in the human transcriptomes of different
tissues [5]. The other enriched type is alternative 3′ splice
(1.6 times). Examples of these types of alternative splicing
and their G tracts are shown in Figure 3B: the alternative
3′ splicing of the exon 5 of PAX8 (paired box 8), alternative
5′ splicing of the exon 22 of MYH13 (myosin, heavy chain
13, skeletal muscle), skipped exon (cassette) 2 of ABCC11
(ATP-binding cassette, sub-family C (CFTR/MRP), member
11) and retained intron 1 of TRERF1 (transcriptional regu-
lating factor 1).
The REPA G-tracts are splicing silencers
To determine the role of the G-tracts in alternative spli-
cing, we examined four REPA G tract-harboring 3′SS by
Figure 3 The REPA G tracts-associated types of alternative splicing and examples of exons (genes) with the major types. A. Pie-shaped
distribution of the relative abundance of different types of alternative splicing associated with the 627 REPA G tracts. The transcriptome-wide data
was based on that by Wang et al., Nature’08. The biggest increase in the G tract group is the retained intron over that in the human transcriptomes.
B. Examples of the major types of alternative splicing associated with the 3′SS G tracts. The exon numbers or gene names are indicated above or to
the right of the splicing diagrams. Horizontal bar: G tract locations. Black boxes: alternative exons/introns. Narrower boxes: untranslated regions of
mRNA. The intron/exon boundaries of alternative 3′ splice sites are indicated by arrowheads. The G tracts or G/A-rich motifs are underlined in the
sequences. Black dots: potential branch points within the consensus “curay”.
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derived from the human beta-globin gene (Figure 4A,
upper left). Three of them almost abolished the usage of
the immediate downstream (proximal) 3′AG and acti-
vated substantial usage of a further downstream cryptic
3′SS within the exon or caused exon skipping (upper
right, lanes 3, 5 and 7). The other one reduced the prox-
imal 3′AG usage by about 22.4% (lane 9). Importantly,
mutating the Gs to As of the REPA G tracts almost
completely (lanes 4 and 10) or partially (lanes 6 and 8)
restored the usage of the proximal 3′AG, accompanied
by abolished (lane 4), reduced (lane 6) or increased (lane
8) cryptic splicing. This suggests that the G tracts are
more than just a purine-rich spacer between the Py and 3′
AG, which also weakens the 3′ splice site (see the MAX-
ENT score and also Figure 2A). The G tracts inhibit the
usage of proximal 3′AG but often activate distal 3′AG,consistent with their increased association with alternative
3′SS (Figure 3A) and the dependence of the effect on their
location relative to the target splice site. Moreover, the
ΔGs of the potential secondary structures caused by the
mutations, as tested by Mfold [27], do not correlate with
the splicing changes, suggesting that the mutation effect is
not due to a secondary structural change. Therefore, we
conclude that all four REPA G tracts tested are splicing
silencers with the Gs playing critical roles.
In order to examine the role of known G tract-binding
factors hnRNP H/F in splicing through the REPA G tracts,
we carried out RNA interference assays (Figure 4A, lower
panel). Two of the reporters PAX8 and PAK4 almost com-
pletely lost the G tract silencer effect upon knockdown of
hnRNP H/F (lanes 3 & 9) whereas the other two exhibited
about 29.3% and 13.3% decrease in exon skipping (lanes 5
& 7). This is accompanied by abolished (lane 3), reduced
Figure 4 The REPA G tracts are splicing silencers and their related exons are controlled by G tract-binding splicing factors hnRNP H/F
in human cells. A. (Upper left) Diagram of splicing reporter mini-genes and (Lower left) western blot of RNA interference samples of HEK293T
cells using anti-nucleolin and anti-hnRNP H/F antibodies. (Right) agarose gels of RT-PCR products from transiently expressed reporters containing
the G-tract-harboring 3′SS or its G- > A mutants in normal (Above) or RNA interference (Below) human HEK293T cells. Boxes: exons, horizontal
lines: introns. Splicing pathways are indicated by dashed lines above or below the pre-mRNA. Heavy black bar: 3′SS with REPA G tract (WT) or its
G- > A mutant (Mut). ApaI and BglII: restriction-cloning sites. *: cryptic splicing pathway through the distal 3′SS or its product. The percentages
(mean ± S.D., n = 3) of molar amounts of the proximal (prox., upstream the cryptic site) 3′SS- skipped product are indicated below each lane. In
the brackets above the lanes are the MaxEnt scores of the G tract or mutant 3′ splice sites of the minigenes. For PRMT5, the scores are −6.01 and
−2.39, respectively. The vector DUP175 has a score of 9.50. B. (Left) western blot of RNA interference samples of HeLa cells as in A. (Right) Agarose gels of
RT-PCR products of endogenous REPA G-tract-harboring genes in HeLa cells. The percentages (%, mean ± S.D., n = 3) of molar amounts of the minor
isoforms (exon excluded “Excl.” except SLC44A2 as inclusion “Incl.”) are below each lane. Black dots: exon included, open circle: exon excluded. @: a
shorter product consistent with a variant in frog. *: non-specific products by sequencing results.
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product. Notably, the mutated mini-genes showed almost
no change in exon skipping (lanes 4, 6 & 10) except one
that showed about 12.7% decrease (lane 8) but still 10.4%
less than its wild type. The mutants also showed reduced
cryptic splicing in the cases of PRMT5 and GRK5 (lanes 6
and 8), suggesting that usage of the cryptic splice sites arealso affected by other hnRNP H/F target element(s) in the
reporter. Hence, the silencer effect of REPA G tract on
exon skipping or its activation of cryptic 3′SS usage is
mainly through hnRNP H/F.
To further validate the G tract silencer effect on spli-
cing of endogenous exons, we used RNA interference of
hnRNP H/F in human HeLa cells and measured the
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(Figure 4B). We tested 8 exons of the above 4 and 4
additional genes. We were able to successfully detect
expression and alternative splicing of 6 exons in this cell
line (Figure 4B). All of them showed an increased exon
inclusion (SLC44A2) or a reduced exon skipping (of the
minor isoform) upon hnRNP H/F knockdown (p < 0.001).
Thus, the G-tract-binding factors hnRNP H/F are essential
repressors of all of the six exons of endogenous genes
tested, consistent with the silencing effect of the G tracts
in splicing reporters (Figure 4A).The REPA G tracts emerged mostly in the ancestors of
mammals during evolution
To determine the evolutionary origin of the G tracts, we
analyzed 22 3′SS in multiple species ranging from fish
to humans. We were able to determine the presence or
absence of 15 of them in every class of animals analyzed
(Table 1). G tracts of 10 of these 3′SS (~67%) were also
found early as in marsupials, four of them (~27%) in
other mammals and only two of them in birds, reptiles
and fish. Therefore, it is likely that most of the G tracts
(~87%) emerged in ancestors of mammals.Table 1 The REPA G tracts among vertebrates
# Gene symbol Transcript ID Exon rank Exon size (bp) 3′SS
1 CAMK1 ENST00000256460 9 79 gtc
2 CNOT3 ENST00000358389 3 276 gttc
3 DUSP12 ENST00000367943 5 187 gttt
4 FES ENST00000328850 6 138 ccg
5 TRPV1 ENST00000174621 7 180 gctc
6 SLC44A2 ENST00000380614 22 104 ccgg
7 RQCD1 ENST00000273064 7 92 tttt
8 PFN2 ENST00000239940 2 193 tttg
9 PDZK1 ENST00000339729 6 197 gttg
10 LRRC23 ENST00000007969 6 137 gcc
11 LAMB1 ENST00000222399 22 225 ttta
12 C3orf62 ENST00000343010 2 92 acct
13 PRMT5 ENST00000324366 3 86 ggtg
14 PAOX ENST00000368534 2 159 tgtt
15 METTL13 ENST00000367736 2 176 cctg
16 MICA ENST00000364810 4 288 gctg
17 FAM113 ENST00000309144 4 239 ggg
18 PAX8 ENST00000263334 5 176 cccg
19 ABCC11 ENST00000356608 2 117 ttct
20 HLA-G ENST00000383504 3 276 aagg
21 HLA-H ENST00000360432 3 276 cggg
ND: not determined.As an example, the mammal-specific emergence of the
G pentamer in CaMK1 is shown in Figure 5. Besides the
full length CaMK1, there is a shorter transcript (GenBank
accession # AB209395) with the retention of introns 8 and
9 within the 3′ untranslated region (UTR, Figure 5). The
G pentamer GGGGG is at the upstream 3′SS of exon
9, where it might weaken the 3′SS to promote intron
retention.
Alignment of the CaMK1 3′SS from 22 species indi-
cates that the G pentamer (or tetramer in two species) is
present in mammals from human to opossum but not in
wallaby and platypus, nor is it present in chicken, lizard,
frog or fish. Interestingly, there are three Gs in wallaby
and two Gs in platypus, both interrupted by a single T.
It thus seems that the G tracts emerged in mammalian
ancestors but were lost in some marsupials.
The mostly mammalian emergence of the REPA G
tracts is consistent with the conclusion that G triplets
are more abundant in mammalian than in fish introns as
previously reported in a genome-wide study [28].
Taken together, the examined REPA G tracts are mostly
mammalian gene-specific, suggesting that they may have
evolved to inhibit the splicing of a group of mammalian
exons.−15 ~ −1 nt Presence (1) or Absence (0) of REPA G tract
Other mammals Marsupials Birds Reptiles Fish
ttgggggtttag 1 1 0 0 0
tgtgggggcag 1 1 0 0 0
gggggttgcag 1 1 0 0 0
tctcgggggcag 1 1 0 0 0
cccgggggcag 1 0 0 0 0
ggggagcccag 1 1 0 0 0
gggggaaacag 1 1 0 0 0
gtggggggcag 1 0 0 0 0
ggggagggtag 1 1 0 0 0
ctgggggtctag 1 0 0 0 0
tcgggtgacag 1 0 0 0 0
gggggctgcag 1 1 0 0 0
ggggagtgcag 1 1 0 0 0
tgcgggggaag 1 1 1 1 1
ggcgggggcag 1 1 1 1
ggtgggggcag 1 1 0 ND ND
gggggtgggtag 1 1 ND 0 0
gggggtaccag 1 1 ND 0 0
gggaaacgaag 1 0 ND 0 0
ggtggggccag 1 1 ND ND ND
ggcggggccag 1 1 ND ND ND
Figure 5 An example of evolutionary emergence of REPA G tracts between the polypyrimidine tract and 3′AG within the upstream 3′
SS of alternative exons of mammalian genes. Shown is an alignment of sequences around the 3′SS of the CaMK1 gene from 22 species. The
G tract (black bar in diagram) is at the 3′SS of intron 8 (in front of the exon 9). Retention of both upstream and downstream introns around exon
9 generates a splice variant with an alternative stop codon in the upstream intron (Genbank accession number AB209395). In most other
transcripts, both introns are spliced. Arrowhead: intron/exon boundary. It can be seen from the alignment that the G pentamer is present in most
mammals. It is absent in wallaby, platypus, birds and the other vertebrates shown here.
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with cancer
To determine whether these G tract-harboring 3′SS are
associated with any specific biological functions or dis-
eases, we analyzed 578 mapped genes of the 627 3′SS in
the dataset in the Ingenuity Pathway Analyses. In this
search, we also included 6 sets of randomly chosen
human genes from the ENSEMBL genome database to
control the specificity of the analysis. The result indi-
cates that the 578 genes are markedly enriched for genes
involved in cancer (444 genes in total, Figure 6, and see
also Additional file 1: Tables S2-S3 for a complete list),
by about 4 fold -log(p-value) over the 6 sets of randomly
chosen genes. Particularly melanoma, carcinoma and solid
tumors have the most significant enrichment of these
genes, including ABCC11 (melanoma drug resistance),
SNRNP200 (retinitis pigmentosa), TRERF1 (breast cancer)
and WTX (Wilms tumor gene on X chromosome, Wilms
tumor) [29-33]. SNRNP200 together with another seven
genes encode splicing factors: HNRNPH1, HNRNPH3,
KHSRP, MBNL1, PPAN, PRPF8, SNRPN. Particularly in-
teresting is the hnRNP H1 and H3, which are G tract-
binding proteins themselves, predicting an auto-regulatory
circuit through alternative splicing. Moreover, most of the
genes in Figures 3, 4 and 5 (except PCED1A) are involved
in cancer as well (see also Additional file 1: Table S3). Fur-
thermore, similar Ingenuity pathway analysis using the full
set of the G3–8 3′SS-containing genes reached the same
conclusion. Therefore, the REPA G tracts are significantlyenriched in genes involved in cancer, likely to control their
alternative splicing and cancer properties.
As an example of the genes involved in cancer, the
WTX (or called AMER1, APC membrane recruitment
protein 1) has a retained intron with a 3′SS G3 in its
second exon [34] (Figure 6C). The full length transcript
encodes an 1135aa protein that interacts with the tran-
scription factor WT1 (Wilms tumor 1) and efficiently
enhances its transcriptional activity [30,35]. The in-
tron splicing results in a shorter protein of 804aa lacking
the WT1-interacting domain. The shorter isoform has
reduced effect on WT1 transcriptional activity [30,35].
Therefore, the 3′ REPA G tract-associated intron re-
tention/splicing determine the high or low activity of
the tumor suppressor WTX. Presence of the G tract
appears to favor the full activity of the protein, likely
by weakening the 3′ splice site and thus promoting intron
retention.
Also enriched are biological functions associated with
organismal survival (about 2.5 fold –log(p-value)), and to
some extent cellular growth & proliferation (Figure 6A-B,
and Additional file 1: Table S2).
Taken together, more than six hundred 3′SS that
harbour REPA G tracts associated with alternative spli-
cing are identified in the human genome. Instead of
being enhancers as the other mammalian intronic G
tracts, these specially localized G tracts appear to be intro-
nic splicing silencers and mostly emerged in the ancestors
of mammals. Moreover, their host genes are highly
Figure 6 Significantly clustered functions of the REPA G tract-harboring genes. A. Shown is a bar graph of the –log (p-value) for the
significance level of the functional comparison of 578 genes of the 627 3′SS (left most dark blue column in each functional category) with six
random sets (2nd -7th column in each category) of 1319 human genes each. Brownish horizontal line: significance threshold of the functions/diseases
of these genes above the background levels (random events) in the Ingenuity database. B. Heat map of the different cancers/biological functions with
top log p values of enrichment. A scale bar with the color intensity/-log p value is to the upper right corner of the map. C. The WTX gene’s REPA G
tract and alternative splicing as an example of genes involved in cancer whose alternative splicing (intron retention) causes a functional impact on
gene function. The intron retention or splicing results in two isoforms of different lengths with different interaction with WT1 and effects on the latter’s
transcriptional activity (Upper panel). The shorter isoform lacks the WT1-interaction domain at the COOH terminus (Lower panel).
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have evolved de novo RNA elements within this highly
constrained space of 3′ splice site to alter the mRNA pro-
cessing step for diverse proteins in particular cellular
functions.Discussion
Regulatory RNA elements between Py and 3′AG (REPA)
The splicing regulatory elements can be outside or over-
lap with the splice site motifs. However, since the loca-
tion and sequences of the polypyrimidine tract and 3′
AG have been more or less constrained for many splice
sites, emergence of de novo regulatory elements between
them has not been observed frequently. A G-rich se-
quence was identified in a group of drosophila genes but
it was enriched further upstream (60nt) in the intron to
inhibit splicing [24]. While the previously reported
CaRRE1 of the STREX exon support the existence of
REPA elements [16], here the identification of a large
group of 3′SS G tracts clearly demonstrate that the emer-
gence of de novo regulatory elements do occur at this lo-
cation, apparently for the regulation of alternative splicing
mainly in mammals. Moreover, these elements are
location-dependent silencers of the immediate down-
stream 3′AG (Figure 4A), instead of enhancers as
found for the other mammalian intronic G tractsoutside of the region between Py and 3′AG
[21,22,24,36]. Beyond G tracts, there are also other
purine-rich elements identified in this search that
await further detailed analysis to reveal their function
in splicing regulation. Furthermore, this also implies the
existence of other non-purine-rich elements. In fact, we
have also observed UGCAUG elements at this location of
alternative exons (Xie, unpublished observation). There-
fore, the repertoires of REPA will apparently increase in
the future. Overall, the REPA provides a distinct example
for the variations of splice sites to cause alternative usage
of exons [37].Variations of splice sites for alternative splicing and
proteomic diversity during evolution
Splicing regulatory RNA elements have evolved from fish
to humans with dramatic emergence of some additional
elements including G tracts [28]. Here the REPA G tracts
appear to have evolved mostly in mammalian ancestors,
evident from the alignment of 3′SS of multiple species
(Figure 5 and Table 1). The evolved elements likely in-
crease the possibility for alternative splicing and cause
functional changes of the proteins (Figure 6). Moreover,
their recruitment of trans-acting factors, such as hnRNP
H/F (Figure 4), would make it possible for upstream sig-
naling to reach the target splice site [38], adding a
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of more REPAs in the genome (Figures 1 and 2), more di-
verse protein isoforms and functions of mammalian genes
could be generated.
Role of G tracts and alternative splicing in cancer
Accumulating evidence indicate that alternative splicing
has been exploited by cancer cells to favor their survival
[39,40]. G tracts have been found to control the alterna-
tive splicing of genes involved in cancer, such as Bcl-x
[22,41]. Their trans-acting factors have also been found
to regulate alternative splicing during tumorigenesis. For
instance, upregulation of hnRNP H in gliomas drives the
IG20 to anti-apoptotic MADD (MAP-kinase activating
death domain protein) splicing in favor of invasiveness
[42]. In HeLa cells, hnRNP H/F upregulates the pro-
apoptosis variant Bcl-xS [41]. Multiple G-tracts can also
form a stable four strand structure called a G quadruple
that is less represented in exon sequences [43]. They are
formed in a cell-cycle-dependent way with the highest
abundance in the S phase [44], and have been proposed
as therapeutic targets for diseases including cancer, for
example, by controlling oncogene transcription [45,46].
They are also proposed to control alternative splicing of
the tumor suppressor p53 [47], and the telomere RNA
hTERT [48]. Multiple copies of G tracts are also seen in
some of the 3′SS examined here. For example the 3′SS
of exon 4 of the matrix-remodeling associated 8 (MXRA8)
gene has five copies of G2–5 within 50 nt of the intron
end. Whether G quadruples may form and play a role in
the control of alternative splicing of some of these cancer-
related genes will need future studies.
In summary, the identification of hundreds of human
3′SS containing the REPA G tracts and the confirmed
splicing silencer effect of representative ones suggest
that the highly constrained 3′SS region has been permis-
sive for the emergence of de novo regulatory elements
for splicing control of a large group of mammalian genes.
Their significant enrichment in genes involved in cancer
implies that their regulation of splicing perhaps control
certain properties of cancer cells.
Conclusions
A large group of human 3′SS have evolved purine-rich
elements between the Py and 3′AG. Particularly the G
tract elements are splicing silencers requiring hnRNP H/
F for their activity. Such G tract-harboring human genes
are significantly enriched for functions related to cancer.
These data demonstrate that the often highly constrained
space between the Py and 3′AG has been remarkably per-
missive for the evolution of splicing regulatory elements,
likely to diversify protein functions in mammals. The pres-
ence of such elements at the 3′SS is also predictive
of alternative splice sites.Methods
Plasmid construction
Splicing reporters with 3′SS REPA or human G-tract
mutant were created by replacing the corresponding up-
stream 3′SS of the middle constitutive exon of DUP175
as carried out previously [49].
Cell culture and transfection
HEK293T cells were grown in Dulbecco’s modified
Eagle’s medium containing 10% new-born calf serum and
1% penicillin/streptomycin/glutamine solution (Invitrogen).
Transfection of overnight cultures of HEK293T cells was
performed with Lipofectamine 2000 (Invitrogen) according
to manufacturer’s protocol, using 0.25 μg of splicing
reporter minigene plasmids in 12-well plates. Transfection
of siRNA into HeLa cells was done with Lipofectamine
RNAiMAX (Invitrogen) according to manufacturer’s
instructions.
RNA interference
To knock down hnRNP H/F in HeLa cells, we synthesized
siRNA targeting the 20 nucleotide sequence GCGACC-
GAGAACGACAUUU [41]. HeLa cells were transfected
with 360 pmoles of siRNA twice in 6-well plates with 24-
hour intervals. Cells were harvested after 72 hours of first
transfection for protein and RNA analysis.
RT-PCR
We performed semi-quantitative RT-PCR of endogenous
genes based on previously described procedure [15].
Specifically, in 10 ul reverse transcription reactions we
used 250 ng of cytoplasmic RNA and used 0.75 ul of it
in a 12.5 ul PCR reaction for 30 cycles (24 for mini-genes)
with annealing temperature of 60°C. We quantified bands
intensities using ImageJ (National Institutes of Health).
Human genome search
We wrote a bioperl script (Additional file 2: REPA_Perl)
to search the 3′SS in the annotated EMSEMBL human
genome for purine rich motifs within −10 ~ −3 position
at intron ends. The consensus elements were identified
using the −15 ~ −3 nucleotides by the MEME program
as described previously [25]. The MaxEntScan entropy
scores of 3′SS were determined as described [26], using
23 nt (20 nt intron and 3 nt exon) of the 3′SS at the
Burge lab website (http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq_acc.html). Human genome se-
quence was downloaded from the ENSEMBL website
(http://uswest.ensembl.org/index.html). HGNC symbols of
genes containing identified 3′ spice sites were retrieved
from Biomart (http://www.biomart.org/index.html) using
ENSEMBL gene IDs. From these 3′SS, we determined the
alternative exons by alignment with that in the UCSC Gen-
ome Browser (http://www.genome.ucsc.edu/index.html);
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were excluded from further analysis. We used
ENSEMBL gene IDs to obtain the clusters of identified
genes involved in same functions/diseases using Ingenuity
Pathway Analysis application (www.ingenuity.com).
Statistical analyses
Entropy scores were compared with two-tailed Student’s
t-test in Figure 2A. Ingenuity pathway analysis was by
right-tailed Fisher’s exact test in Figure 6B. The abun-
dance of purine nucleotides or alternative splicing was
compared by hypergeometric test in Figures 1B and 2B,
respectively.
Notes
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